Key facts
- This page summarizes Walter Klemp V's Form 4 filing for Moleculin Biotech, Inc. (MBRX).
- 8 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 23 Jun 2025, 16:35.
Walter Klemp V - 20 Jun 2025 Form 4 Insider Report for Moleculin Biotech, Inc. (MBRX)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- MBRX
- Reported as of
- 20 Jun 2025
- Net transaction value
- +$249,171
- SEC form
- 4
- Accepted by SEC
- 23 Jun 2025, 16:35:11 UTC
- Prior SEC filing
- 18 Jun 2025
- Next SEC filing
- 13 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan P. Foster by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Walter Klemp V filed Form 4 for Moleculin Biotech, Inc. (MBRX) on 23 Jun 2025.
Change
- Previous filing in this sequence was filed on 18 Jun 2025.
- Current net transaction value: +$249,171.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0000938419
Primary reporting owner
KLEMP WALTER V
- Relationship
- CEO and President, Director
- Address
- C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON
- Signature
- /s/ Jonathan P. Foster by Power of Attorney
- Signature date
- 23 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,750
- Change %
- +6.4%
- Price
- Shares after
- 62,046
- Date
- 20 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
MBRX
transaction
Common Stock
Tax liability
- Transaction value
- $244
- Shares
- -914
- Change %
- -1.5%
- Price
- $0.2670
- Shares after
- 61,132
- Date
- 20 Jun 2025
- Ownership
- Direct
- Footnotes
- F2
MBRX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +8,990
- Change %
- +15%
- Price
- Shares after
- 70,122
- Date
- 22 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
MBRX
transaction
Common Stock
Tax liability
- Transaction value
- $585
- Shares
- -2,190
- Change %
- -3.1%
- Price
- $0.2670
- Shares after
- 67,932
- Date
- 22 Jun 2025
- Ownership
- Direct
- Footnotes
- F2
MBRX
transaction
Common Stock
Purchase
- Transaction value
- $250,000
- Shares
- +675,675
- Change %
- +995%
- Price
- $0.3700
- Shares after
- 743,607
- Date
- 23 Jun 2025
- Ownership
- Direct
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,750
- Change %
- -0.95%
- Price
- $0.000000
- Shares after
- 391,446
- Date
- 20 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- Footnotes
- F1, F3
MBRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -8,990
- Change %
- -2.3%
- Price
- $0.000000
- Shares after
- 382,456
- Date
- 22 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,990
- Exercise price
- Footnotes
- F1, F4
MBRX
transaction
Derivative
Series E Warrants
Purchase
- Transaction value
- Shares
- -2,027,025
- Change %
- -46%
- Price
- Shares after
- 2,409,481
- Date
- 23 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,027,025
- Exercise price
- $0.3700
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Restricted stock units convert into common stock on a one-for-one basis.
Footnote F2
Shares withheld for payment of taxes upon vesting of restricted stock unit awards.
Footnote F3
On June 20, 2022, the reporting person was granted 15,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Footnote F4
On June 22, 2023, the reporting person was granted 35,959 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Footnote F5
On June 23, 2025, the reporting person acquired 675,675 shares of common stock and Series E warrants to purchase 2,027,025 shares of common stock at a purchase price of $0.37 per share and accompanying warrants in a public offering. The Series E warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series E warrants and will expire five years from the date of such approval.